Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Rifamycin-mode of action, resistance, and biosynthesis.

Floss HG, Yu TW.

Chem Rev. 2005 Feb;105(2):621-32. Review. No abstract available.

PMID:
15700959
2.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. Epub 2008 Apr 28.

3.

Mu-induced rifamycin-resistant mutations not located in the rpoB gene of Escherichia coli.

Kollenda MC, Kamp D, Hartmann GR.

Mol Gen Genet. 1986 Jul;204(1):192-4.

PMID:
3528757
4.

Rifamycin SV and related ansamycins.

Chiao JS, Xia TH, Mei BG, Jin ZK, Gu WL.

Biotechnology. 1995;28:477-98. Review. No abstract available.

PMID:
8688635
5.

Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins.

Artsimovitch I, Vassylyeva MN, Svetlov D, Svetlov V, Perederina A, Igarashi N, Matsugaki N, Wakatsuki S, Tahirov TH, Vassylyev DG.

Cell. 2005 Aug 12;122(3):351-63.

6.
7.

Rifamycin S and its geometric isomer produced by a newly found actinomycete, Micromonospora rifamycinica.

Huang H, Wu X, Yi S, Zhou Z, Zhu J, Fang Z, Yue J, Bao S.

Antonie Van Leeuwenhoek. 2009 Feb;95(2):143-8. doi: 10.1007/s10482-008-9297-0. Epub 2009 Jan 6.

PMID:
19125348
8.

Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.

Gualtieri M, Villain-Guillot P, Latouche J, Leonetti JP, Bastide L.

Antimicrob Agents Chemother. 2006 Jan;50(1):401-2. No abstract available.

9.
10.

[RNA polymerase-rifamycin. A molecular model of inhibition].

Chertov OIu, Obukhov AN, Lipkin VM.

Bioorg Khim. 1983 May;9(5):633-40. Russian.

PMID:
6207842
11.

Rifamycins: strain improvement program.

Lal R, Khanna M, Kaur H, Srivastava N, Tripathi KK, Lal S.

Crit Rev Microbiol. 1995;21(1):19-30. Review.

PMID:
7576149
12.

Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents.

Chopra I.

Curr Opin Investig Drugs. 2007 Aug;8(8):600-7. Review.

PMID:
17668362
13.

Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors.

Josa D, da Cunha EF, Ramalho TC, Souza TC, Caetano MS.

J Biomol Struct Dyn. 2008 Feb;25(4):373-6.

PMID:
18092831
14.

Recent trends in rifamycin research.

Lal R, Lal S.

Bioessays. 1994 Mar;16(3):211-6. Review.

PMID:
7513153
15.

Antibiotic biosynthesis: from natural to unnatural compounds.

Floss HG.

J Ind Microbiol Biotechnol. 2001 Sep;27(3):183-94. Review.

PMID:
11780790
16.

Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin.

Vitali B, Turroni S, Serina S, Sosio M, Vannini L, Candela M, Guerzoni ME, Brigidi P.

Int J Antimicrob Agents. 2008 Jun;31(6):555-60. doi: 10.1016/j.ijantimicag.2008.02.002. Epub 2008 May 6.

PMID:
18462927
17.

Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes.

Mullin S, Rothstein DM, Murphy CK.

Antimicrob Agents Chemother. 2006 May;50(5):1908-9. No abstract available.

18.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. Epub 2008 Apr 28.

19.

Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.

Li J, Ma Z, Chapo K, Yan D, Lynch AS, Ding CZ.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5510-3. Epub 2007 Aug 28.

PMID:
17826091
20.

Supplemental Content

Support Center